QWM
FENC icon

Quaker Wealth Management’s Fennec Pharmaceuticals FENC Stock Holding History

Quaker Wealth Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160
Closed -$1.23K – 990
2025
Q4 		$1.23K Buy
+160
New +$1.31K ﹤0.01% 502

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Quaker Wealth Management's FENC Position: Q1 2026 in Review

Quaker Wealth Management sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 160 shares — an estimated $1.23K sold.

Quaker Wealth Management first reported a position in FENC in Q4 2025 and held it in 1 quarter. The position peaked at $1.23K in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Quaker Wealth Management reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quaker Wealth Management sold 160 Fennec Pharmaceuticals shares in Q1 2026, an estimated $1.23K.
  • Quaker Wealth Management first reported a position in Fennec Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Quaker Wealth Management's Fennec Pharmaceuticals position peaked at $1.23K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Quaker Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.